LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $100.20.

Several research firms have recently issued reports on LMAT. Wells Fargo & Company lowered their target price on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. Barrington Research reiterated an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Monday, November 10th. Finally, Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisors Asset Management Inc. boosted its holdings in LeMaitre Vascular by 3.0% in the 2nd quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock worth $341,000 after buying an additional 118 shares during the last quarter. Johnson Investment Counsel Inc. boosted its stake in shares of LeMaitre Vascular by 0.5% in the third quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock worth $2,607,000 after acquiring an additional 153 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after acquiring an additional 155 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of LeMaitre Vascular by 2.2% during the third quarter. Jones Financial Companies Lllp now owns 7,486 shares of the medical instruments supplier’s stock worth $630,000 after purchasing an additional 158 shares in the last quarter. Finally, Illinois Municipal Retirement Fund raised its stake in LeMaitre Vascular by 1.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 11,048 shares of the medical instruments supplier’s stock valued at $967,000 after purchasing an additional 171 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $83.83 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of 36.13, a PEG ratio of 1.89 and a beta of 0.68. The firm’s 50 day simple moving average is $84.70 and its 200-day simple moving average is $87.34. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $105.55.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. The firm had revenue of $61.05 million for the quarter, compared to the consensus estimate of $62.18 million. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th were given a $0.20 dividend. The ex-dividend date was Thursday, November 20th. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.48%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.